SHR-A2102: Clinical Trials

7 trials of SHR-A2102, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 recruiting, 2 unknown, 1 not yet recruiting. 7 Phase 1, 4 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 17Recruiting 4, Unknown 2, Not yet recruiting 1
Phase 24Recruiting 3, Unknown 1

Follow SHR-A2102: new trials by email Literature Review of SHR-A2102 trials Research Report on SHR-A2102

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase Ib Study of HS-10504 Combined Therapy in NSCLC
HS-10504, SHR-A2009, HS-20122 - Lung Cancer
Phase 1Not yet recruitingJiangsu Hansoh Pharmaceutical Co., Ltd.4002026-03-302026-02-17
A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer
SHR-A2102, Adebrelimab, Cetuximab - Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Phase 1 / Phase 2RecruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.2102025-07-112026-07-20
A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma
SHR-A2102, Adebrelimab injection, SHR-8068 injection - Advanced Urothelial Carcinoma
Phase 1 / Phase 2RecruitingShanghai Hengrui Pharmaceutical Co., Ltd.902024-11-042024-11-18
A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
SHR-A2102, Adebelimab (SHR-1316), SHR-8068 - Non-Small Cell Lung Cancer
Phase 1 / Phase 2UnknownShanghai Hengrui Pharmaceutical Co., Ltd.1242024-09-272024-11-12
A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors
SHR-A2102, SHR-A2102 ; Adebrelimab injection, SHR-A2102 + Disitamab Vedotin For Injection - Advanced Solid Tumors
Phase 1 / Phase 2RecruitingShanghai Hengrui Pharmaceutical Co., Ltd.802024-05-272026-08-24
Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
SHR-A2102 - Advanced Solid Tumors
Phase 1RecruitingShanghai Hengrui Pharmaceutical Co., Ltd.3952023-04-062025-07-22
A Phase 1 Study of SHR-A2102 in Subjects With Advanced Solid Tumors.
SHR-A2102 - Advanced Or Metastatic Solid Tumor Malignancies
Phase 1UnknownShanghai Hengrui Pharmaceutical Co., Ltd.2522023-03-032023-03-28

Conditions studied

Carcinoma, Non-Small-Cell Lung (1)  ·  Lung Neoplasms (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)

Sponsors

Shanghai Hengrui Pharmaceutical Co., Ltd. (5)  ·  Jiangsu Hansoh Pharmaceutical Co., Ltd. (1)  ·  Suzhou Suncadia Biopharmaceuticals Co., Ltd. (1)

Countries

China (6)

Results publications

PMID 42636836